Influenza & Respiratory

 

 

This event will tackle the latest issues affecting vaccines for respiratory diseases including influenza, TB, RSV and MERS to stimulate the industry to develop more effective vaccines. Ensure you use this event to make people aware of your expertise around key topics such as universal and seasonal flu, maternal immunization and pandemic preparedness.

 

Who Attends

 

• Pharma
• Biotech
• National and International Government
• Non-Profit Organizations
• Academics And Research Institutions

 

Job Titles

 

• CEO / CSO / COO
• CMO / Head of Scientific Affairs
• Head of Influenza
• Head of Infectious Disease
• Head of R&D
• Head of Regulatory Affairs
• Head of Manufacturing
• Head of Immunology

Who Should Sponsor?

 

• Platform Technology Providers
• Biotechs
• Big Pharma
• Logistics / Cold Chain

 

Influenza and Respiratory Vaccines, Tuesday 16 April 2019

Influenza and Respiratory Vaccines
09:00

Chair's opening remarks

Universal and Pandemic Influenza Vaccines

James Crowe
Influenza and Respiratory Vaccines
09:10

Universal flu: are we any closer to finding the “holy “grail”? The Grand Challenge

  • 100 years on from the most severe influenza pandemic in recorded history, what have we learnt that’s translational to a universal solution
  • The multifactorial challenges involved in bringing innovation and improvement to flu products by building more rapid capabilities
  • Newest research in universal influenza vaccines and their potential impact on the flu market
Influenza and Respiratory Vaccines
10:10

What we’ve learnt 100 years on for respiratory trials

Senior representative, PPD
10:40

Networking Coffee Break

Influenza and Respiratory Vaccines
11:40

Ph3 efficacy results a VLP influenza vaccine

Senior representative, Medicago
Dr Sean Tucker
Influenza and Respiratory Vaccines
12:40

Ph2 oral vaccine for protection against influenza challenge in humans

Scot Roberts
Influenza and Respiratory Vaccines
12:55

Ph2 NasoVAX report, a replication-deficient adenovirus vector technology intranasally delivered

13:10

Networking Lunch & Poster Session

Influenza and Respiratory Vaccines
14:40

Utilizing human challenge studies to accelerate the development of respiratory vaccines

Senior representative, hVIVO

RSV Vaccines

Influenza and Respiratory Vaccines
15:10

Novel insights in RSV transmission from animal models

Reserved for Viroclinics Biosciences
Peter Kwong
Influenza and Respiratory Vaccines
15:40

Structural vaccinology - RSV

16:09

Networking Coffee Break

Gregory Glenn
Influenza and Respiratory Vaccines
16:40

Ph3 and beyond: The RSV F nanoparticle vaccine for infants via maternal immunization

Ilse Dieussaert
Influenza and Respiratory Vaccines
17:10

GSK’s RSV vaccine pipeline update

Dr Christopher Heery
Influenza and Respiratory Vaccines
17:40

Ongoing development of a novel vaccine for Respiratory Syncytial Virus

  • An overview of preclinical, phase 1 data and recent phase 2 results
  • Development aspects unique to RSV and immunologic correlates
  • Potential avenues for next steps in demonstrating vaccine efficacy and receiving regulatory approval
Influenza and Respiratory Vaccines
17:55

The reveal: Introduction to a new RSV vaccine

18:10

Chair’s Closing Remarks per co-lo and Close of Congress Day 2

18:15

Off-site Networking Drinks, follow the congress team

last published: 14/Dec/18 13:15

Influenza and Respiratory Vaccines, Wednesday 17 April 2019

Influenza and Respiratory Vaccines
09:00

Chair's opening remarks

Respiratory Infections Strategy & Control

Dr Tim Hirst
Influenza and Respiratory Vaccines
09:40

A new broad-spectrum vaccine against Streptococcus pneumoniae

Michael Schrader
Influenza and Respiratory Vaccines
09:55

MIMIX Flu, is a broadly protective, shelf-stable, self-administered influenza vaccine

10:40

Networking Coffee Break

Sanjay Sethi
Influenza and Respiratory Vaccines
11:30

COPD panel: The interplay of virus, bacterial pathogens and exacerbation, an opportunity for vaccines?

12:30

Networking Lunch & Poster Session

DAY 3 AFTERNOON PLENARY OF CONGRESS: RENAISSANCE BALLROOM

Paul Offit
Dr Saad Omer
14:55

A framework for a comprehensive maternal immunization platform

  • Evidence for current immunization recommendations
  • Maternal vaccines in development
  • The need for evidence-based interventions at the practice, provider, and patient levels to ensure higher vaccination levels
Dr Timothy Cooke
16:00

Chair Closing Remarks and End of Congress

last published: 14/Dec/18 13:15

Sign Up for Event Updates

Get Involved At World Vaccine Congress Washington

 

To Sponsor Or Exhibit

Marc Rhys-Evans
marc.rhys-evans@terrapinn.com
+44 20 7827 5945

 

 

 

To Register

Tayyab Abbasi
tayyab.abbasi@terrapinn.com
+44 20 7092 1210

 

 

 

Press Relations

Karina Kusova
karina.kusova@terrapinn.com
+44 20 7092 1071